Cargando…
Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers
Pneumococcal meningitis (PM), caused by Streptococcus pneumonia, remains a high-burden disease in developing countries. Antibiotic therapy has been limited due to the inefficiency of drug transport across the blood-brain barrier (BBB) and the emergence of drug-resistant strains. In our preliminary s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225518/ https://www.ncbi.nlm.nih.gov/pubmed/30404541 http://dx.doi.org/10.1080/10717544.2018.1486473 |
_version_ | 1783369794096988160 |
---|---|
author | Hong, Wei Zhang, Zehui Liu, Lipeng Zhao, Yining Zhang, Dexian Liu, Mingchun |
author_facet | Hong, Wei Zhang, Zehui Liu, Lipeng Zhao, Yining Zhang, Dexian Liu, Mingchun |
author_sort | Hong, Wei |
collection | PubMed |
description | Pneumococcal meningitis (PM), caused by Streptococcus pneumonia, remains a high-burden disease in developing countries. Antibiotic therapy has been limited due to the inefficiency of drug transport across the blood-brain barrier (BBB) and the emergence of drug-resistant strains. In our preliminary study, PEGylated nano-self-assemblies of bacitracin A (PEGylated Nano-BA(12K)) demonstrated a strong antibacterial potency against S. pneumonia. In this study, the potential application of this micelle for the treatment of both Penicillin-sensitive and -resistant PM was studied. To address BBB-targeting and -crossing issues, PEGylated Nano-BA(12K) was formulated with a specific brain-targeting peptide (rabies virus glycopeptide-29, RVG(29)) and a P-glycoprotein inhibitor (Pluronic(®) P85 unimers) to construct a mixed micellar system (RVG(29)-Nano-BA(P85)). RVG(29)-Nano-BA(P85) demonstrated a strong antibacterial potency against 13 clinical isolates of S. pneumonia, even higher than that of Penicillin G, a conventional anti-PM agent. RVG(29)-Nano-BA(P85) had more cellular uptake in brain capillary endothelial cells (BCECs) and higher BBB-crossing efficiency than single formulated Nano-BAs as shown in an in vitro BBB model. The enhanced BBB-permeability was attributed to the synergetic effect of RVG(29) and P85 unimers through receptor-mediated transcytosis, exhaustion of ATP, and reduction in membrane microviscosity. In vivo results further demonstrated that RVG(29)-Nano-BA(P85) was able to accumulate in brain parenchyma as confirmed by in vivo optical imaging. In addition, RVG(29)-Nano-BA(P85) exhibited high therapeutic efficiencies in both Penicillin-sensitive and -resistant PM mouse models with negligible systemic toxicity. Collectively, RVG(29)-Nano-BA(P85) could effectively overcome BBB barriers and suppressed the growth of both drug-sensitive and -resistant S. pneumonia in the brain tissues, which demonstrated its potential for the treatment of PM. |
format | Online Article Text |
id | pubmed-6225518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-62255182018-11-13 Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers Hong, Wei Zhang, Zehui Liu, Lipeng Zhao, Yining Zhang, Dexian Liu, Mingchun Drug Deliv Research Article Pneumococcal meningitis (PM), caused by Streptococcus pneumonia, remains a high-burden disease in developing countries. Antibiotic therapy has been limited due to the inefficiency of drug transport across the blood-brain barrier (BBB) and the emergence of drug-resistant strains. In our preliminary study, PEGylated nano-self-assemblies of bacitracin A (PEGylated Nano-BA(12K)) demonstrated a strong antibacterial potency against S. pneumonia. In this study, the potential application of this micelle for the treatment of both Penicillin-sensitive and -resistant PM was studied. To address BBB-targeting and -crossing issues, PEGylated Nano-BA(12K) was formulated with a specific brain-targeting peptide (rabies virus glycopeptide-29, RVG(29)) and a P-glycoprotein inhibitor (Pluronic(®) P85 unimers) to construct a mixed micellar system (RVG(29)-Nano-BA(P85)). RVG(29)-Nano-BA(P85) demonstrated a strong antibacterial potency against 13 clinical isolates of S. pneumonia, even higher than that of Penicillin G, a conventional anti-PM agent. RVG(29)-Nano-BA(P85) had more cellular uptake in brain capillary endothelial cells (BCECs) and higher BBB-crossing efficiency than single formulated Nano-BAs as shown in an in vitro BBB model. The enhanced BBB-permeability was attributed to the synergetic effect of RVG(29) and P85 unimers through receptor-mediated transcytosis, exhaustion of ATP, and reduction in membrane microviscosity. In vivo results further demonstrated that RVG(29)-Nano-BA(P85) was able to accumulate in brain parenchyma as confirmed by in vivo optical imaging. In addition, RVG(29)-Nano-BA(P85) exhibited high therapeutic efficiencies in both Penicillin-sensitive and -resistant PM mouse models with negligible systemic toxicity. Collectively, RVG(29)-Nano-BA(P85) could effectively overcome BBB barriers and suppressed the growth of both drug-sensitive and -resistant S. pneumonia in the brain tissues, which demonstrated its potential for the treatment of PM. Taylor & Francis 2018-11-07 /pmc/articles/PMC6225518/ /pubmed/30404541 http://dx.doi.org/10.1080/10717544.2018.1486473 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hong, Wei Zhang, Zehui Liu, Lipeng Zhao, Yining Zhang, Dexian Liu, Mingchun Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers |
title | Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers |
title_full | Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers |
title_fullStr | Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers |
title_full_unstemmed | Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers |
title_short | Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic(®) P85 unimers |
title_sort | brain-targeted delivery of pegylated nano-bacitracin a against penicillin-sensitive and -resistant pneumococcal meningitis: formulated with rvg(29) and pluronic(®) p85 unimers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225518/ https://www.ncbi.nlm.nih.gov/pubmed/30404541 http://dx.doi.org/10.1080/10717544.2018.1486473 |
work_keys_str_mv | AT hongwei braintargeteddeliveryofpegylatednanobacitracinaagainstpenicillinsensitiveandresistantpneumococcalmeningitisformulatedwithrvg29andpluronicp85unimers AT zhangzehui braintargeteddeliveryofpegylatednanobacitracinaagainstpenicillinsensitiveandresistantpneumococcalmeningitisformulatedwithrvg29andpluronicp85unimers AT liulipeng braintargeteddeliveryofpegylatednanobacitracinaagainstpenicillinsensitiveandresistantpneumococcalmeningitisformulatedwithrvg29andpluronicp85unimers AT zhaoyining braintargeteddeliveryofpegylatednanobacitracinaagainstpenicillinsensitiveandresistantpneumococcalmeningitisformulatedwithrvg29andpluronicp85unimers AT zhangdexian braintargeteddeliveryofpegylatednanobacitracinaagainstpenicillinsensitiveandresistantpneumococcalmeningitisformulatedwithrvg29andpluronicp85unimers AT liumingchun braintargeteddeliveryofpegylatednanobacitracinaagainstpenicillinsensitiveandresistantpneumococcalmeningitisformulatedwithrvg29andpluronicp85unimers |